Search research articles
Contact Us
Filters
Showing results (331-340 of 353) with videos related to
Page
of 36
Sort By:
Investigational New Drugs
|
March 18, 2015
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies
David C Smith, Thea Kalebic, Jeffrey R Infante, et al.
Lung India : Official Organ of Indian Chest Society
|
November 14, 2023
Position statement of the Indian Chest Society on reinstatement of the Respiratory Medicine department in undergraduate medical colleges in India
Radha Munje, Rakesh Chawla, Ravindran Chetambath, et al.
British Journal of Haematology
|
May 10, 2017
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma
Shaji Kumar, Philippe Moreau, Parameswaran Hari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2009
Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies
Chiung-Ing Wong, Tong-San Koh, Ross Soo, et al.
Journal of Hematology & Oncology
|
July 8, 2017
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study
Jian Hou, Jie Jin, Yan Xu, et al.
Clinical Pharmacology and Therapeutics
|
May 16, 2024
Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper
Divya Samineni, Karthik Venkatakrishnan, Ahmed A Othman, et al.
The Lancet. Oncology
|
December 3, 2014
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study
Shaji K Kumar, Jesus G Berdeja, Ruben Niesvizky, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 15, 2011
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure
Nizar M Tannir, Yu-Ning Wong, Christian K Kollmannsberger, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 21, 2011
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer
Eng-Huat Tan, Glenwood D Goss, Ravi Salgia, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology
|
February 13, 2026
Food Allergy in India: Delphi Consensus Statement by Indian Academy of Pediatrics (IAP)-Allergy and Applied Immunology Chapter
Sowmya Arudi Nagarajan, Soundarya Mahalingam, Neeraj Gupta, et al.
Page
of 36
Search research articles
Search
Showing results (331-340 of 353) with videos related to
Sort By:
Page
of 36
Investigational New Drugs
|
March 18, 2015
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies
David C Smith, Thea Kalebic, Jeffrey R Infante, et al.
Lung India : Official Organ of Indian Chest Society
|
November 14, 2023
Position statement of the Indian Chest Society on reinstatement of the Respiratory Medicine department in undergraduate medical colleges in India
Radha Munje, Rakesh Chawla, Ravindran Chetambath, et al.
British Journal of Haematology
|
May 10, 2017
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma
Shaji Kumar, Philippe Moreau, Parameswaran Hari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2009
Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies
Chiung-Ing Wong, Tong-San Koh, Ross Soo, et al.
Journal of Hematology & Oncology
|
July 8, 2017
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study
Jian Hou, Jie Jin, Yan Xu, et al.
Clinical Pharmacology and Therapeutics
|
May 16, 2024
Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper
Divya Samineni, Karthik Venkatakrishnan, Ahmed A Othman, et al.
The Lancet. Oncology
|
December 3, 2014
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study
Shaji K Kumar, Jesus G Berdeja, Ruben Niesvizky, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 15, 2011
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure
Nizar M Tannir, Yu-Ning Wong, Christian K Kollmannsberger, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 21, 2011
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer
Eng-Huat Tan, Glenwood D Goss, Ravi Salgia, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology
|
February 13, 2026
Food Allergy in India: Delphi Consensus Statement by Indian Academy of Pediatrics (IAP)-Allergy and Applied Immunology Chapter
Sowmya Arudi Nagarajan, Soundarya Mahalingam, Neeraj Gupta, et al.
Page
of 36